XBI stock forecast, quote, news & analysis

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL).

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

The average market capitalization across the SPDR® S&P Biotech ETF ETF is 9.38B. The market cap for tickers in the group ranges from 148.01M to 322.43B. ABBV holds the highest valuation in this group at 322.43B. The lowest valued company is CABA at 148.01M.

The average weekly price growth across all stocks in the SPDR® S&P Biotech ETF ETF was -12%. For the same ETF, the average monthly price growth was -8%, and the average quarterly price growth was 1%. TNGX experienced the highest price growth at 31%, while CABA experienced the biggest fall at -33%.

The average weekly volume growth across all stocks in the SPDR® S&P Biotech ETF ETF was 25%. For the same stocks of the ETF, the average monthly volume growth was 83% and the average quarterly volume growth was 84%